Informing Pain Treatment Using Pharmacogenomic Analysis

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Chicago
Study ID
NCT06511401
Status
Recruiting
Apply to this trial

Conditions

  • Adult Patients Who Are Receiving Oncologic Care

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pharmacogenomic (PGx) results. — OTHER
    These results are designed to provide specific dosing information based on the participant's unique genetics/genomics.

Study Details

This is a randomized, prospective study to evaluate the effects of preemptive pharmacogenomic (PGx) testing on opioid dosing decisions/selections and pain score in cancer patients.

Key Dates

Start date
Jul 30, 2024
Status verified
Apr 2026
Primary completion
Jan 7, 2028
Completion
Mar 31, 2028

Study Design

Enrollment
800 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: PGx Arm
    PGX information is provided to clinicals to inform opioid dosing and selection.
  • No Intervention: Control Arm
    No PGX information provided opioid dosing and selection is according to standard of care.

Primary Outcome Measure

Pain control. [ Time Frame: 45 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Chicago Medicine Comprehensive Cancer CenterChicagoIllinois60637
Clinical Trials Intake
[email protected]
855-702-8222
Peter O'Donnell (PRINCIPAL_INVESTIGATOR)

Find similar trials in Chicago, IL

By research site
University of Chicago Medicine Comprehensive Cancer Center· Chicago, IL